Article information
Full text is only aviable in PDF
Bibliografía
[1.]
F. Baquero Mochales.
ENIR.
Estudio Nacional de la Infección Respiratoria. Estudio descriptivo, Gabinete de Estudios Sociológicos, (1990),
[2.]
D.E. Craven, K.A. Steger, T.W. Barber.
Preventing nosocomial pneumonia: state of the art and perspectives for the 1990's.
Am J Med, 91 (1991), pp. 44-53
[3.]
L.J. Nisbet, J.W. Westley.
Developments in microbial products screening.
Annu Rep Med Chem, 21 (1986), pp. 149-157
[4.]
The Economist.
Molecules and markets: a survey of pharmaceuticals.
The Economist, 303 (1987), pp. 3-14
[5.]
A.L. Hillman, J.M. Eisenberg, M.V. Pauly, B.S. Bloom, H. Glick, B. Kinorian, et al.
Avoiding bias in the conduct and reporting of costeffectiveness research sponsored by pharmaceutical companies.
N Engl J Med, 324 (1991), pp. 1.362-1.365
[6.]
A.W. Chow, C.B. Hall, J.O. Klein, R.B. Kammer, R.D. Meyer, J.S. Remington.
Evaluation of new antiinfective drugs for the treatment of respiratory tract infections.
Clin Infect Dis, 15 (1992), pp. 62-88
[7.]
D.A. Kessler, W.L. Pines.
The federal regulation of prescription drug advertising and promotion.
JAMA, 264 (1991), pp. 2.409-2.415
[8.]
G.D. Fang, M. Fine, J. Orloff, D. Arisumi, V.L. Yu, W. Kapour, et al.
New and emerging etiologies for community-acquired pneumonia with implication for therapy: a prospective multicenter study of 359 cases.
Medicine (Baltimore), 69 (1990), pp. 307-316
[9.]
D.E. Craven, K.A. Steger.
Epidemiology of nosocomial pneumonia. New perspectives on an old disease.
Chest, 108 (1995), pp. 1-16
[10.]
R. Alonso, A. Fernández-Araguiz, K. Colom, and the Spanish Group for the Study of Ofloxacin Resistance.
Antimicrobial susceptibility of Streptococcus pneumoniae.
Sevilla: 6th European Congress of Clinical Microbiology and Infectious Diseases, (1993),
[11.]
E. Bouza, neumocócica. Infección.
Patrones de susceptibilidad antibiótica en España.
Enferm Infecc Microbiol Clin, 11 (1993), pp. 15-22
[12.]
J.M. García Arenzana, M. Montes, N. Gómez, E. Pérez Trallero.
Resistencia a eritromicina en Streptococcus pneumoniae.
Enferm Infecc Microbiol Clin, 9 (1991), pp. 613-618
[13.]
C. Sánchez, R. Armengol, J. Lite, I. Mir, J. Garau.
Penicillin-resistant pneumococci and community-acquired pneumococcal pneumonia.
Lancet, 339 (1992), pp. 988
[14.]
A.M.S. Figueiredo, J.D. Connor, A. Severin, M. Vitoria, V. Pato, A. Tomasz.
A pmneumococcal clinical isolate with high-level resistance to cefotaxime and ceftriaxone.
Antimicrob Agents Chemother, 36 (1992), pp. 886-889
[15.]
A.L. Barry, J.H. Jorgensen, D.J. Hardy, S.D. Allen, C.N. Baker.
Haemophilus influenzae ATCC 49766, an alternative quality control strain for monitoring broth microdilution susceptibility tests with selected (beta)-lactams.
J Clin Microbiol, 30 (1992), pp. 2.033-2.037
[16.]
G.S. Itokazu, L. Danziger.
Ampicillin-sulbactam and ticarcillin-clavulanic acid: a comparison of their in vitro activity and review of their clinical efficacy.
Pharmacotherapy, 11 (1991), pp. 382-414
[17.]
N. Joshi, D. Milfred.
The use and misuse of new antibiotics. A perspective.
Arch Intern Med, 155 (1995), pp. 569-577
[18.]
J.J. Picazo, C. Rodríguez Avial.
Haemophilus influenzae y Moraxella catarrhalis frente a los antimicrobianos de administración oral.
Enferm Infecc Microbiol Clin, 11 (1993), pp. 10-14
[19.]
A.M. Geddes.
Cefpodoxime proxetil in the treatment of lower respiratory tract infections.
Drugs, 42 (1991), pp. 34-40
[20.]
J.G. Bartlett, L.M. Mundy.
Community-acquired pneumonia.
N Engl J Med, 333 (1995), pp. 1.618-1.624
[21.]
E. Pérez Trallero.
Infecciones bacterianas respiratorias adquiridas en la comunidad: estrategias terapéuticas.
Enferm Infecc Microbiol Clin, 11 (1993), pp. 51-62
[22.]
J.J. Gordon, C.A. Kauffman.
Superinfections with Streptococcus pneumoniae during therapy with ciprofloxacin.
Am J Med, 89 (1990), pp. 383-384
[23.]
M.C. Sullivan, B.W. Cooper, C.H. Nightingale, R. Quintiliani, M.T. Lawlor.
Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model.
Antimicrob Agents Chemother, 37 (1993), pp. 234-239
[24.]
H.A. Blumber, D. Rimland, D.J. Carroll, P. Terry, I.K. Wachsmuth.
Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus.
J Infect Dis, 163 (1991), pp. 1.279-1.285
[25.]
D. Maddix, L. Warner.
Do we need an intravenous fluorquinolone?.
West J Med, 157 (1992), pp. 55-59
[27.]
R.P. Gaynes, D.H. Culver.
Resistance to imipenem among selected gram-negative bacilli in the United States.
Infect Control Hosp Epidemiol, 13 (1992), pp. 10-14
[28.]
D.P. Nicolau, C.D. Freeman, P.P. Belliveau, C.H. Nightingale, J.W. Ross, R. Quintiliani.
Experience with a once-daily aminoglycoside program administered to 2.184 adult patients.
Antimicrob Agents Chemother, 39 (1995), pp. 650-655
[29.]
W. Craig.
Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens.
Eur J Clin Microbiol Infect Dis, 12 (1993), pp. 6-8
[30.]
J.R. Kerr, J.G. Barr, E.T.M. Smyth.
Computerised calculation of the true costs on antibiotic therapy.
Eur J Clin Microbiol Infect Dis, 12 (1993), pp. 622-625
[31.]
S.R. Norrby.
Future trends in antibiotic therapy.
Scand J Infect Dis, (1992), pp. 41-45
[32.]
J.A. Carton, J.A. Maradona, G. Pérez del Molino, V. Asensi.
Tendencias registradas en el empleo de antimicrobianos en un hospital español entre 1986 y 1991.
Med Clin (Barc), 100 (1993), pp. 761-765
[33.]
G. Medoff.
Antimicrobial use in otolaryngeal infections: general considerations.
Ann Otol Rhinol Laryngol, 101 (1992), pp. 5-8
Copyright © 1997. Sociedad Española de Neumología y Cirugía Torácica
